Universal Health Services, Inc.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, FSNUY has a market cap of 109.76B. Regarding current trading prices, UHS is priced at $181.80, while FSNUY trades at $12.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas FSNUY's P/E ratio is 27.07. In terms of profitability, UHS's ROE is +0.18%, compared to FSNUY's ROE of +0.02%. Regarding short-term risk, UHS is more volatile compared to FSNUY. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, HCA has a market cap of 85.12B. Regarding current trading prices, UHS is priced at $181.80, while HCA trades at $353.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas HCA's P/E ratio is 15.70. In terms of profitability, UHS's ROE is +0.18%, compared to HCA's ROE of -2.36%. Regarding short-term risk, UHS is more volatile compared to HCA. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, RVLWF has a market cap of 38.58B. Regarding current trading prices, UHS is priced at $181.80, while RVLWF trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas RVLWF's P/E ratio is -0.30. In terms of profitability, UHS's ROE is +0.18%, compared to RVLWF's ROE of +3.95%. Regarding short-term risk, UHS is more volatile compared to RVLWF. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, FSNUF has a market cap of 21.25B. Regarding current trading prices, UHS is priced at $181.80, while FSNUF trades at $37.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas FSNUF's P/E ratio is 20.85. In terms of profitability, UHS's ROE is +0.18%, compared to FSNUF's ROE of +0.02%. Regarding short-term risk, UHS is less volatile compared to FSNUF. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, FMS has a market cap of 16.64B. Regarding current trading prices, UHS is priced at $181.80, while FMS trades at $28.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas FMS's P/E ratio is 23.83. In terms of profitability, UHS's ROE is +0.18%, compared to FMS's ROE of +0.04%. Regarding short-term risk, UHS is more volatile compared to FMS. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, FMCQF has a market cap of 15.33B. Regarding current trading prices, UHS is priced at $181.80, while FMCQF trades at $52.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas FMCQF's P/E ratio is 21.86. In terms of profitability, UHS's ROE is +0.18%, compared to FMCQF's ROE of +0.04%. Regarding short-term risk, UHS is less volatile compared to FMCQF. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, THC has a market cap of 13.82B. Regarding current trading prices, UHS is priced at $181.80, while THC trades at $148.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas THC's P/E ratio is 9.54. In terms of profitability, UHS's ROE is +0.18%, compared to THC's ROE of +0.37%. Regarding short-term risk, UHS is more volatile compared to THC. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, BDUUY has a market cap of 12.84B. Regarding current trading prices, UHS is priced at $181.80, while BDUUY trades at $32.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas BDUUY's P/E ratio is 28.36. In terms of profitability, UHS's ROE is +0.18%, compared to BDUUY's ROE of +0.16%. Regarding short-term risk, UHS is more volatile compared to BDUUY. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, SOLV has a market cap of 12.16B. Regarding current trading prices, UHS is priced at $181.80, while SOLV trades at $70.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas SOLV's P/E ratio is 25.46. In terms of profitability, UHS's ROE is +0.18%, compared to SOLV's ROE of +0.15%. Regarding short-term risk, UHS is less volatile compared to SOLV. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, EHC has a market cap of 11.73B. Regarding current trading prices, UHS is priced at $181.80, while EHC trades at $116.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas EHC's P/E ratio is 23.95. In terms of profitability, UHS's ROE is +0.18%, compared to EHC's ROE of +0.25%. Regarding short-term risk, UHS is more volatile compared to EHC. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, BDULF has a market cap of 11.66B. Regarding current trading prices, UHS is priced at $181.80, while BDULF trades at $0.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas BDULF's P/E ratio is 23.67. In terms of profitability, UHS's ROE is +0.18%, compared to BDULF's ROE of +0.16%. Regarding short-term risk, UHS is less volatile compared to BDULF. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, DVA has a market cap of 11.05B. Regarding current trading prices, UHS is priced at $181.80, while DVA trades at $143.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas DVA's P/E ratio is 13.40. In terms of profitability, UHS's ROE is +0.18%, compared to DVA's ROE of +1.81%. Regarding short-term risk, UHS is more volatile compared to DVA. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, BDUUF has a market cap of 10.49B. Regarding current trading prices, UHS is priced at $181.80, while BDUUF trades at $0.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas BDUUF's P/E ratio is 22.00. In terms of profitability, UHS's ROE is +0.18%, compared to BDUUF's ROE of +0.16%. Regarding short-term risk, UHS is less volatile compared to BDUUF. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, JDHIY has a market cap of 10.40B. Regarding current trading prices, UHS is priced at $181.80, while JDHIY trades at $3.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas JDHIY's P/E ratio is 18.06. In terms of profitability, UHS's ROE is +0.18%, compared to JDHIY's ROE of +0.05%. Regarding short-term risk, UHS is more volatile compared to JDHIY. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, JDHIF has a market cap of 10.33B. Regarding current trading prices, UHS is priced at $181.80, while JDHIF trades at $3.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas JDHIF's P/E ratio is 26.92. In terms of profitability, UHS's ROE is +0.18%, compared to JDHIF's ROE of +0.05%. Regarding short-term risk, UHS is less volatile compared to JDHIF. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, IHHHF has a market cap of 9.70B. Regarding current trading prices, UHS is priced at $181.80, while IHHHF trades at $1.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas IHHHF's P/E ratio is 15.71. In terms of profitability, UHS's ROE is +0.18%, compared to IHHHF's ROE of +0.09%. Regarding short-term risk, UHS is less volatile compared to IHHHF. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, OSH has a market cap of 9.52B. Regarding current trading prices, UHS is priced at $181.80, while OSH trades at $39.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas OSH's P/E ratio is -17.65. In terms of profitability, UHS's ROE is +0.18%, compared to OSH's ROE of +4.64%. Regarding short-term risk, UHS is more volatile compared to OSH. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, CHE has a market cap of 8.35B. Regarding current trading prices, UHS is priced at $181.80, while CHE trades at $570.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas CHE's P/E ratio is 27.85. In terms of profitability, UHS's ROE is +0.18%, compared to CHE's ROE of +0.26%. Regarding short-term risk, UHS is more volatile compared to CHE. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, ENSG has a market cap of 7.86B. Regarding current trading prices, UHS is priced at $181.80, while ENSG trades at $136.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas ENSG's P/E ratio is 25.79. In terms of profitability, UHS's ROE is +0.18%, compared to ENSG's ROE of +0.17%. Regarding short-term risk, UHS is more volatile compared to ENSG. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, LHCG has a market cap of 5.29B. Regarding current trading prices, UHS is priced at $181.80, while LHCG trades at $169.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas LHCG's P/E ratio is 82.83. In terms of profitability, UHS's ROE is +0.18%, compared to LHCG's ROE of +0.04%. Regarding short-term risk, UHS is more volatile compared to LHCG. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, OPCH has a market cap of 5.21B. Regarding current trading prices, UHS is priced at $181.80, while OPCH trades at $31.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas OPCH's P/E ratio is 25.47. In terms of profitability, UHS's ROE is +0.18%, compared to OPCH's ROE of +0.15%. Regarding short-term risk, UHS is less volatile compared to OPCH. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, RMSYF has a market cap of 5.06B. Regarding current trading prices, UHS is priced at $181.80, while RMSYF trades at $22.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas RMSYF's P/E ratio is 440.00. In terms of profitability, UHS's ROE is +0.18%, compared to RMSYF's ROE of +0.18%. Regarding short-term risk, UHS is less volatile compared to RMSYF. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, BUGDF has a market cap of 5.02B. Regarding current trading prices, UHS is priced at $181.80, while BUGDF trades at $6.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas BUGDF's P/E ratio is 24.27. In terms of profitability, UHS's ROE is +0.18%, compared to BUGDF's ROE of +0.28%. Regarding short-term risk, UHS is less volatile compared to BUGDF. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, RMYHY has a market cap of 5.00B. Regarding current trading prices, UHS is priced at $181.80, while RMYHY trades at $5.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas RMYHY's P/E ratio is 513.00. In terms of profitability, UHS's ROE is +0.18%, compared to RMYHY's ROE of +0.18%. Regarding short-term risk, UHS is less volatile compared to RMYHY. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, ANHGY has a market cap of 4.05B. Regarding current trading prices, UHS is priced at $181.80, while ANHGY trades at $5.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas ANHGY's P/E ratio is 23.87. In terms of profitability, UHS's ROE is +0.18%, compared to ANHGY's ROE of N/A. Regarding short-term risk, UHS is more volatile compared to ANHGY. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, BUHPF has a market cap of 3.86B. Regarding current trading prices, UHS is priced at $181.80, while BUHPF trades at $4.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas BUHPF's P/E ratio is 18.65. In terms of profitability, UHS's ROE is +0.18%, compared to BUHPF's ROE of +0.28%. Regarding short-term risk, UHS is less volatile compared to BUHPF. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, AMED has a market cap of 3.13B. Regarding current trading prices, UHS is priced at $181.80, while AMED trades at $95.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas AMED's P/E ratio is 35.17. In terms of profitability, UHS's ROE is +0.18%, compared to AMED's ROE of +0.10%. Regarding short-term risk, UHS is more volatile compared to AMED. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, SGRY has a market cap of 3.05B. Regarding current trading prices, UHS is priced at $181.80, while SGRY trades at $23.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas SGRY's P/E ratio is -18.02. In terms of profitability, UHS's ROE is +0.18%, compared to SGRY's ROE of -0.09%. Regarding short-term risk, UHS is less volatile compared to SGRY. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, MCVEF has a market cap of 2.98B. Regarding current trading prices, UHS is priced at $181.80, while MCVEF trades at $19.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas MCVEF's P/E ratio is 86.22. In terms of profitability, UHS's ROE is +0.18%, compared to MCVEF's ROE of +0.06%. Regarding short-term risk, UHS is less volatile compared to MCVEF. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, ORPEF has a market cap of 2.29B. Regarding current trading prices, UHS is priced at $181.80, while ORPEF trades at $14.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas ORPEF's P/E ratio is 0.03. In terms of profitability, UHS's ROE is +0.18%, compared to ORPEF's ROE of +0.91%. Regarding short-term risk, UHS is less volatile compared to ORPEF. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, LFST has a market cap of 2.23B. Regarding current trading prices, UHS is priced at $181.80, while LFST trades at $5.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas LFST's P/E ratio is -63.67. In terms of profitability, UHS's ROE is +0.18%, compared to LFST's ROE of -0.04%. Regarding short-term risk, UHS is less volatile compared to LFST. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, ACHC has a market cap of 2.20B. Regarding current trading prices, UHS is priced at $181.80, while ACHC trades at $23.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas ACHC's P/E ratio is 8.58. In terms of profitability, UHS's ROE is +0.18%, compared to ACHC's ROE of +0.09%. Regarding short-term risk, UHS is less volatile compared to ACHC. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, MCVEY has a market cap of 2.16B. Regarding current trading prices, UHS is priced at $181.80, while MCVEY trades at $16.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas MCVEY's P/E ratio is 40.37. In terms of profitability, UHS's ROE is +0.18%, compared to MCVEY's ROE of N/A. Regarding short-term risk, UHS is less volatile compared to MCVEY. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, ARDT has a market cap of 2.08B. Regarding current trading prices, UHS is priced at $181.80, while ARDT trades at $14.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas ARDT's P/E ratio is 8.65. In terms of profitability, UHS's ROE is +0.18%, compared to ARDT's ROE of +0.30%. Regarding short-term risk, UHS is less volatile compared to ARDT. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, ADUS has a market cap of 2.04B. Regarding current trading prices, UHS is priced at $181.80, while ADUS trades at $110.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas ADUS's P/E ratio is 25.09. In terms of profitability, UHS's ROE is +0.18%, compared to ADUS's ROE of +0.08%. Regarding short-term risk, UHS is less volatile compared to ADUS. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, SEM has a market cap of 1.92B. Regarding current trading prices, UHS is priced at $181.80, while SEM trades at $14.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas SEM's P/E ratio is 24.04. In terms of profitability, UHS's ROE is +0.18%, compared to SEM's ROE of +0.10%. Regarding short-term risk, UHS is less volatile compared to SEM. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, AMEH has a market cap of 1.83B. Regarding current trading prices, UHS is priced at $181.80, while AMEH trades at $40.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas AMEH's P/E ratio is 39.25. In terms of profitability, UHS's ROE is +0.18%, compared to AMEH's ROE of +0.06%. Regarding short-term risk, UHS is less volatile compared to AMEH. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, ASTH has a market cap of 1.67B. Regarding current trading prices, UHS is priced at $181.80, while ASTH trades at $29.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas ASTH's P/E ratio is 33.01. In terms of profitability, UHS's ROE is +0.18%, compared to ASTH's ROE of +0.06%. Regarding short-term risk, UHS is less volatile compared to ASTH. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, TTALF has a market cap of 1.64B. Regarding current trading prices, UHS is priced at $181.80, while TTALF trades at $12.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas TTALF's P/E ratio is 19.33. In terms of profitability, UHS's ROE is +0.18%, compared to TTALF's ROE of +0.15%. Regarding short-term risk, UHS is more volatile compared to TTALF. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, BKD has a market cap of 1.60B. Regarding current trading prices, UHS is priced at $181.80, while BKD trades at $6.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas BKD's P/E ratio is -6.58. In terms of profitability, UHS's ROE is +0.18%, compared to BKD's ROE of -0.66%. Regarding short-term risk, UHS is less volatile compared to BKD. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, NHC has a market cap of 1.55B. Regarding current trading prices, UHS is priced at $181.80, while NHC trades at $100.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas NHC's P/E ratio is 15.40. In terms of profitability, UHS's ROE is +0.18%, compared to NHC's ROE of +0.11%. Regarding short-term risk, UHS is less volatile compared to NHC. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, RYHTY has a market cap of 1.54B. Regarding current trading prices, UHS is priced at $181.80, while RYHTY trades at $7.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas RYHTY's P/E ratio is -21.06. In terms of profitability, UHS's ROE is +0.18%, compared to RYHTY's ROE of +0.00%. Regarding short-term risk, UHS is more volatile compared to RYHTY. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, RHCGF has a market cap of 1.43B. Regarding current trading prices, UHS is priced at $181.80, while RHCGF trades at $1.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas RHCGF's P/E ratio is -20.14. In terms of profitability, UHS's ROE is +0.18%, compared to RHCGF's ROE of -0.02%. Regarding short-term risk, UHS is less volatile compared to RHCGF. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, MD has a market cap of 1.25B. Regarding current trading prices, UHS is priced at $181.80, while MD trades at $14.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas MD's P/E ratio is -14.52. In terms of profitability, UHS's ROE is +0.18%, compared to MD's ROE of -0.13%. Regarding short-term risk, UHS is less volatile compared to MD. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, BKDT has a market cap of 1.23B. Regarding current trading prices, UHS is priced at $181.80, while BKDT trades at $77.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas BKDT's P/E ratio is N/A. In terms of profitability, UHS's ROE is +0.18%, compared to BKDT's ROE of -0.66%. Regarding short-term risk, UHS is more volatile compared to BKDT. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, AGL has a market cap of 1.19B. Regarding current trading prices, UHS is priced at $181.80, while AGL trades at $2.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas AGL's P/E ratio is -4.62. In terms of profitability, UHS's ROE is +0.18%, compared to AGL's ROE of -0.42%. Regarding short-term risk, UHS is less volatile compared to AGL. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, LTGHF has a market cap of 1.18B. Regarding current trading prices, UHS is priced at $181.80, while LTGHF trades at $0.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas LTGHF's P/E ratio is 11.70. In terms of profitability, UHS's ROE is +0.18%, compared to LTGHF's ROE of +0.29%. Regarding short-term risk, UHS is less volatile compared to LTGHF. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, LWSCF has a market cap of 1.15B. Regarding current trading prices, UHS is priced at $181.80, while LWSCF trades at $12.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas LWSCF's P/E ratio is 41.52. In terms of profitability, UHS's ROE is +0.18%, compared to LWSCF's ROE of +0.09%. Regarding short-term risk, UHS is more volatile compared to LWSCF. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, LTGHY has a market cap of 1.13B. Regarding current trading prices, UHS is priced at $181.80, while LTGHY trades at $3.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas LTGHY's P/E ratio is 10.33. In terms of profitability, UHS's ROE is +0.18%, compared to LTGHY's ROE of +0.40%. Regarding short-term risk, UHS is less volatile compared to LTGHY. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, USPH has a market cap of 1.13B. Regarding current trading prices, UHS is priced at $181.80, while USPH trades at $74.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas USPH's P/E ratio is 40.27. In terms of profitability, UHS's ROE is +0.18%, compared to USPH's ROE of +0.05%. Regarding short-term risk, UHS is less volatile compared to USPH. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, RAFLF has a market cap of 1.11B. Regarding current trading prices, UHS is priced at $181.80, while RAFLF trades at $0.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas RAFLF's P/E ratio is 20.00. In terms of profitability, UHS's ROE is +0.18%, compared to RAFLF's ROE of +0.04%. Regarding short-term risk, UHS is less volatile compared to RAFLF. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, AVAH has a market cap of 1.05B. Regarding current trading prices, UHS is priced at $181.80, while AVAH trades at $5.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas AVAH's P/E ratio is -90.00. In terms of profitability, UHS's ROE is +0.18%, compared to AVAH's ROE of +0.08%. Regarding short-term risk, UHS is less volatile compared to AVAH. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, RKAGY has a market cap of 1.05B. Regarding current trading prices, UHS is priced at $181.80, while RKAGY trades at $7.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas RKAGY's P/E ratio is 21.22. In terms of profitability, UHS's ROE is +0.18%, compared to RKAGY's ROE of +0.03%. Regarding short-term risk, UHS is less volatile compared to RKAGY. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, HCSG has a market cap of 1.04B. Regarding current trading prices, UHS is priced at $181.80, while HCSG trades at $14.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas HCSG's P/E ratio is 25.95. In terms of profitability, UHS's ROE is +0.18%, compared to HCSG's ROE of +0.08%. Regarding short-term risk, UHS is more volatile compared to HCSG. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, RHKJF has a market cap of 1.02B. Regarding current trading prices, UHS is priced at $181.80, while RHKJF trades at $15.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas RHKJF's P/E ratio is 21.55. In terms of profitability, UHS's ROE is +0.18%, compared to RHKJF's ROE of +0.03%. Regarding short-term risk, UHS is less volatile compared to RHKJF. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, PNTG has a market cap of 985.12M. Regarding current trading prices, UHS is priced at $181.80, while PNTG trades at $28.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas PNTG's P/E ratio is 40.83. In terms of profitability, UHS's ROE is +0.18%, compared to PNTG's ROE of +0.12%. Regarding short-term risk, UHS is less volatile compared to PNTG. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, NWKHY has a market cap of 945.10M. Regarding current trading prices, UHS is priced at $181.80, while NWKHY trades at $7.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas NWKHY's P/E ratio is 13.22. In terms of profitability, UHS's ROE is +0.18%, compared to NWKHY's ROE of +0.13%. Regarding short-term risk, UHS is less volatile compared to NWKHY. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, EXETF has a market cap of 857.21M. Regarding current trading prices, UHS is priced at $181.80, while EXETF trades at $10.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas EXETF's P/E ratio is 16.05. In terms of profitability, UHS's ROE is +0.18%, compared to EXETF's ROE of +0.69%. Regarding short-term risk, UHS is more volatile compared to EXETF. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, AMN has a market cap of 840.61M. Regarding current trading prices, UHS is priced at $181.80, while AMN trades at $22.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas AMN's P/E ratio is -5.72. In terms of profitability, UHS's ROE is +0.18%, compared to AMN's ROE of -0.18%. Regarding short-term risk, UHS is less volatile compared to AMN. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, JXFGF has a market cap of 755.56M. Regarding current trading prices, UHS is priced at $181.80, while JXFGF trades at $0.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas JXFGF's P/E ratio is 14.00. In terms of profitability, UHS's ROE is +0.18%, compared to JXFGF's ROE of +0.03%. Regarding short-term risk, UHS is less volatile compared to JXFGF. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, WHTCF has a market cap of 708.39M. Regarding current trading prices, UHS is priced at $181.80, while WHTCF trades at $2.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas WHTCF's P/E ratio is 31.12. In terms of profitability, UHS's ROE is +0.18%, compared to WHTCF's ROE of +0.04%. Regarding short-term risk, UHS is more volatile compared to WHTCF. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, KDGTF has a market cap of 675.13M. Regarding current trading prices, UHS is priced at $181.80, while KDGTF trades at $0.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas KDGTF's P/E ratio is -1.67. In terms of profitability, UHS's ROE is +0.18%, compared to KDGTF's ROE of N/A. Regarding short-term risk, UHS is more volatile compared to KDGTF. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, EHAB has a market cap of 519.54M. Regarding current trading prices, UHS is priced at $181.80, while EHAB trades at $10.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas EHAB's P/E ratio is -3.30. In terms of profitability, UHS's ROE is +0.18%, compared to EHAB's ROE of -0.26%. Regarding short-term risk, UHS is less volatile compared to EHAB. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, AUNA has a market cap of 506.25M. Regarding current trading prices, UHS is priced at $181.80, while AUNA trades at $6.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas AUNA's P/E ratio is 15.55. In terms of profitability, UHS's ROE is +0.18%, compared to AUNA's ROE of +0.07%. Regarding short-term risk, UHS is more volatile compared to AUNA. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, TALK has a market cap of 505.45M. Regarding current trading prices, UHS is priced at $181.80, while TALK trades at $3.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas TALK's P/E ratio is 302.00. In terms of profitability, UHS's ROE is +0.18%, compared to TALK's ROE of -0.04%. Regarding short-term risk, UHS is less volatile compared to TALK. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, TALKW has a market cap of 496.39M. Regarding current trading prices, UHS is priced at $181.80, while TALKW trades at $0.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas TALKW's P/E ratio is N/A. In terms of profitability, UHS's ROE is +0.18%, compared to TALKW's ROE of -0.04%. Regarding short-term risk, UHS is more volatile compared to TALKW. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, INNV has a market cap of 491.45M. Regarding current trading prices, UHS is priced at $181.80, while INNV trades at $3.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas INNV's P/E ratio is -19.16. In terms of profitability, UHS's ROE is +0.18%, compared to INNV's ROE of -0.10%. Regarding short-term risk, UHS is less volatile compared to INNV. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, CYH has a market cap of 491.07M. Regarding current trading prices, UHS is priced at $181.80, while CYH trades at $3.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas CYH's P/E ratio is -0.95. In terms of profitability, UHS's ROE is +0.18%, compared to CYH's ROE of +0.30%. Regarding short-term risk, UHS is less volatile compared to CYH. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, WFHG has a market cap of 470.60M. Regarding current trading prices, UHS is priced at $181.80, while WFHG trades at $7.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas WFHG's P/E ratio is N/A. In terms of profitability, UHS's ROE is +0.18%, compared to WFHG's ROE of +0.22%. Regarding short-term risk, UHS is less volatile compared to WFHG. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, SNDA has a market cap of 468.24M. Regarding current trading prices, UHS is priced at $181.80, while SNDA trades at $24.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas SNDA's P/E ratio is -45.96. In terms of profitability, UHS's ROE is +0.18%, compared to SNDA's ROE of -0.03%. Regarding short-term risk, UHS is less volatile compared to SNDA. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, CCRN has a market cap of 459.29M. Regarding current trading prices, UHS is priced at $181.80, while CCRN trades at $14.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas CCRN's P/E ratio is -31.84. In terms of profitability, UHS's ROE is +0.18%, compared to CCRN's ROE of -0.03%. Regarding short-term risk, UHS is less volatile compared to CCRN. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, ORRRY has a market cap of 371.54M. Regarding current trading prices, UHS is priced at $181.80, while ORRRY trades at $0.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas ORRRY's P/E ratio is -0.33. In terms of profitability, UHS's ROE is +0.18%, compared to ORRRY's ROE of +73.42%. Regarding short-term risk, UHS is more volatile compared to ORRRY. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, BTMDW has a market cap of 292.88M. Regarding current trading prices, UHS is priced at $181.80, while BTMDW trades at $1.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas BTMDW's P/E ratio is 0.05. In terms of profitability, UHS's ROE is +0.18%, compared to BTMDW's ROE of -0.06%. Regarding short-term risk, UHS is less volatile compared to BTMDW. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, CMPS has a market cap of 259.81M. Regarding current trading prices, UHS is priced at $181.80, while CMPS trades at $3.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas CMPS's P/E ratio is -1.65. In terms of profitability, UHS's ROE is +0.18%, compared to CMPS's ROE of -0.74%. Regarding short-term risk, UHS is less volatile compared to CMPS. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, MFCSF has a market cap of 252.17M. Regarding current trading prices, UHS is priced at $181.80, while MFCSF trades at $11.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas MFCSF's P/E ratio is 8.09. In terms of profitability, UHS's ROE is +0.18%, compared to MFCSF's ROE of +0.83%. Regarding short-term risk, UHS is less volatile compared to MFCSF. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, EVGRF has a market cap of 237.47M. Regarding current trading prices, UHS is priced at $181.80, while EVGRF trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas EVGRF's P/E ratio is -0.05. In terms of profitability, UHS's ROE is +0.18%, compared to EVGRF's ROE of +0.67%. Regarding short-term risk, UHS is less volatile compared to EVGRF. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, MKLNF has a market cap of 224.32M. Regarding current trading prices, UHS is priced at $181.80, while MKLNF trades at $11.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas MKLNF's P/E ratio is 19.23. In terms of profitability, UHS's ROE is +0.18%, compared to MKLNF's ROE of +0.15%. Regarding short-term risk, UHS is more volatile compared to MKLNF. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, CSU has a market cap of 223.71M. Regarding current trading prices, UHS is priced at $181.80, while CSU trades at $33.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas CSU's P/E ratio is 0.67. In terms of profitability, UHS's ROE is +0.18%, compared to CSU's ROE of +2.23%. Regarding short-term risk, UHS is less volatile compared to CSU. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, BTMD has a market cap of 218.84M. Regarding current trading prices, UHS is priced at $181.80, while BTMD trades at $4.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas BTMD's P/E ratio is 44.44. In terms of profitability, UHS's ROE is +0.18%, compared to BTMD's ROE of -0.06%. Regarding short-term risk, UHS is less volatile compared to BTMD. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, TOI has a market cap of 212.11M. Regarding current trading prices, UHS is priced at $181.80, while TOI trades at $2.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas TOI's P/E ratio is -3.94. In terms of profitability, UHS's ROE is +0.18%, compared to TOI's ROE of -2.73%. Regarding short-term risk, UHS is less volatile compared to TOI. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, AIRS has a market cap of 175.75M. Regarding current trading prices, UHS is priced at $181.80, while AIRS trades at $2.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas AIRS's P/E ratio is -10.31. In terms of profitability, UHS's ROE is +0.18%, compared to AIRS's ROE of -0.21%. Regarding short-term risk, UHS is less volatile compared to AIRS. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, AONC has a market cap of 171.11M. Regarding current trading prices, UHS is priced at $181.80, while AONC trades at $5.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas AONC's P/E ratio is -6.57. In terms of profitability, UHS's ROE is +0.18%, compared to AONC's ROE of +0.25%. Regarding short-term risk, UHS is less volatile compared to AONC. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, JYNT has a market cap of 153.07M. Regarding current trading prices, UHS is priced at $181.80, while JYNT trades at $9.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas JYNT's P/E ratio is -99.90. In terms of profitability, UHS's ROE is +0.18%, compared to JYNT's ROE of -0.00%. Regarding short-term risk, UHS is less volatile compared to JYNT. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, DCGO has a market cap of 139.92M. Regarding current trading prices, UHS is priced at $181.80, while DCGO trades at $1.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas DCGO's P/E ratio is 7.78. In terms of profitability, UHS's ROE is +0.18%, compared to DCGO's ROE of +0.00%. Regarding short-term risk, UHS is less volatile compared to DCGO. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, CHHHF has a market cap of 121.49M. Regarding current trading prices, UHS is priced at $181.80, while CHHHF trades at $1.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas CHHHF's P/E ratio is -39.20. In terms of profitability, UHS's ROE is +0.18%, compared to CHHHF's ROE of -0.06%. Regarding short-term risk, UHS is more volatile compared to CHHHF. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, VTIAF has a market cap of 104.42M. Regarding current trading prices, UHS is priced at $181.80, while VTIAF trades at $5.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas VTIAF's P/E ratio is -3.59. In terms of profitability, UHS's ROE is +0.18%, compared to VTIAF's ROE of +0.11%. Regarding short-term risk, UHS is less volatile compared to VTIAF. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, FVE has a market cap of 98.39M. Regarding current trading prices, UHS is priced at $181.80, while FVE trades at $2.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas FVE's P/E ratio is -5.64. In terms of profitability, UHS's ROE is +0.18%, compared to FVE's ROE of -0.15%. Regarding short-term risk, UHS is less volatile compared to FVE. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, PIII has a market cap of 62.56M. Regarding current trading prices, UHS is priced at $181.80, while PIII trades at $8.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas PIII's P/E ratio is -0.16. In terms of profitability, UHS's ROE is +0.18%, compared to PIII's ROE of -1.07%. Regarding short-term risk, UHS is less volatile compared to PIII. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, PIIIW has a market cap of 58.41M. Regarding current trading prices, UHS is priced at $181.80, while PIIIW trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas PIIIW's P/E ratio is -0.01. In terms of profitability, UHS's ROE is +0.18%, compared to PIIIW's ROE of -1.07%. Regarding short-term risk, UHS is more volatile compared to PIIIW. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, MCIOF has a market cap of 54.04M. Regarding current trading prices, UHS is priced at $181.80, while MCIOF trades at $0.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas MCIOF's P/E ratio is -1.22. In terms of profitability, UHS's ROE is +0.18%, compared to MCIOF's ROE of N/A. Regarding short-term risk, UHS is more volatile compared to MCIOF. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, ASSF has a market cap of 45.35M. Regarding current trading prices, UHS is priced at $181.80, while ASSF trades at $1.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas ASSF's P/E ratio is -33.33. In terms of profitability, UHS's ROE is +0.18%, compared to ASSF's ROE of -6.63%. Regarding short-term risk, UHS is more volatile compared to ASSF. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, KONEF has a market cap of 44.34M. Regarding current trading prices, UHS is priced at $181.80, while KONEF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas KONEF's P/E ratio is N/A. In terms of profitability, UHS's ROE is +0.18%, compared to KONEF's ROE of -6.56%. Regarding short-term risk, UHS is less volatile compared to KONEF. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, ALR has a market cap of 44.18M. Regarding current trading prices, UHS is priced at $181.80, while ALR trades at $1.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas ALR's P/E ratio is -1.11. In terms of profitability, UHS's ROE is +0.18%, compared to ALR's ROE of -0.15%. Regarding short-term risk, UHS is more volatile compared to ALR. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, CCEL has a market cap of 40.77M. Regarding current trading prices, UHS is priced at $181.80, while CCEL trades at $5.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas CCEL's P/E ratio is 504.50. In terms of profitability, UHS's ROE is +0.18%, compared to CCEL's ROE of -0.01%. Regarding short-term risk, UHS is less volatile compared to CCEL. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, IMAC has a market cap of 33.08M. Regarding current trading prices, UHS is priced at $181.80, while IMAC trades at $1.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas IMAC's P/E ratio is -2.27. In terms of profitability, UHS's ROE is +0.18%, compared to IMAC's ROE of +2.46%. Regarding short-term risk, UHS is less volatile compared to IMAC. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, HQDA has a market cap of 18.64M. Regarding current trading prices, UHS is priced at $181.80, while HQDA trades at $0.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas HQDA's P/E ratio is N/A. In terms of profitability, UHS's ROE is +0.18%, compared to HQDA's ROE of +0.00%. Regarding short-term risk, UHS is more volatile compared to HQDA. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, AMS has a market cap of 18.06M. Regarding current trading prices, UHS is priced at $181.80, while AMS trades at $2.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas AMS's P/E ratio is 8.48. In terms of profitability, UHS's ROE is +0.18%, compared to AMS's ROE of +0.09%. Regarding short-term risk, UHS and AMS have similar daily volatility (1.77).

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, MODV has a market cap of 16.79M. Regarding current trading prices, UHS is priced at $181.80, while MODV trades at $1.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas MODV's P/E ratio is -0.08. In terms of profitability, UHS's ROE is +0.18%, compared to MODV's ROE of -8.96%. Regarding short-term risk, UHS is less volatile compared to MODV. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, NVLPF has a market cap of 16.59M. Regarding current trading prices, UHS is priced at $181.80, while NVLPF trades at $0.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas NVLPF's P/E ratio is 9.50. In terms of profitability, UHS's ROE is +0.18%, compared to NVLPF's ROE of +0.08%. Regarding short-term risk, UHS is more volatile compared to NVLPF. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, AIH has a market cap of 15.93M. Regarding current trading prices, UHS is priced at $181.80, while AIH trades at $0.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas AIH's P/E ratio is -2.78. In terms of profitability, UHS's ROE is +0.18%, compared to AIH's ROE of -0.79%. Regarding short-term risk, UHS is less volatile compared to AIH. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, USNU has a market cap of 14.77M. Regarding current trading prices, UHS is priced at $181.80, while USNU trades at $0.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas USNU's P/E ratio is -5.31. In terms of profitability, UHS's ROE is +0.18%, compared to USNU's ROE of -0.81%. Regarding short-term risk, UHS is less volatile compared to USNU. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, CANO has a market cap of 12.43M. Regarding current trading prices, UHS is priced at $181.80, while CANO trades at $2.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas CANO's P/E ratio is -0.01. In terms of profitability, UHS's ROE is +0.18%, compared to CANO's ROE of -32.61%. Regarding short-term risk, UHS is less volatile compared to CANO. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, FPCG has a market cap of 10.25M. Regarding current trading prices, UHS is priced at $181.80, while FPCG trades at $1,025.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas FPCG's P/E ratio is 0.09. In terms of profitability, UHS's ROE is +0.18%, compared to FPCG's ROE of +0.00%. Regarding short-term risk, UHS is more volatile compared to FPCG. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, FTRP has a market cap of 9.81M. Regarding current trading prices, UHS is priced at $181.80, while FTRP trades at $0.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas FTRP's P/E ratio is -1.22. In terms of profitability, UHS's ROE is +0.18%, compared to FTRP's ROE of -0.62%. Regarding short-term risk, UHS is less volatile compared to FTRP. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, NUMIF has a market cap of 8.23M. Regarding current trading prices, UHS is priced at $181.80, while NUMIF trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas NUMIF's P/E ratio is -0.42. In terms of profitability, UHS's ROE is +0.18%, compared to NUMIF's ROE of -1.95%. Regarding short-term risk, UHS is less volatile compared to NUMIF. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, XCRT has a market cap of 7.95M. Regarding current trading prices, UHS is priced at $181.80, while XCRT trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas XCRT's P/E ratio is N/A. In terms of profitability, UHS's ROE is +0.18%, compared to XCRT's ROE of +2.48%. Regarding short-term risk, UHS is less volatile compared to XCRT. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, HLYK has a market cap of 6.62M. Regarding current trading prices, UHS is priced at $181.80, while HLYK trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas HLYK's P/E ratio is -1.17. In terms of profitability, UHS's ROE is +0.18%, compared to HLYK's ROE of +4.66%. Regarding short-term risk, UHS is less volatile compared to HLYK. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, GBCS has a market cap of 6.13M. Regarding current trading prices, UHS is priced at $181.80, while GBCS trades at $2.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas GBCS's P/E ratio is -2.50. In terms of profitability, UHS's ROE is +0.18%, compared to GBCS's ROE of +0.56%. Regarding short-term risk, UHS is more volatile compared to GBCS. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, MNDR has a market cap of 6.00M. Regarding current trading prices, UHS is priced at $181.80, while MNDR trades at $1.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas MNDR's P/E ratio is -0.31. In terms of profitability, UHS's ROE is +0.18%, compared to MNDR's ROE of -5.70%. Regarding short-term risk, UHS is less volatile compared to MNDR. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, GBNH has a market cap of 5.52M. Regarding current trading prices, UHS is priced at $181.80, while GBNH trades at $0.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas GBNH's P/E ratio is -0.06. In terms of profitability, UHS's ROE is +0.18%, compared to GBNH's ROE of +0.51%. Regarding short-term risk, UHS is less volatile compared to GBNH. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, VLXC has a market cap of 5.40M. Regarding current trading prices, UHS is priced at $181.80, while VLXC trades at $0.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas VLXC's P/E ratio is -7.55. In terms of profitability, UHS's ROE is +0.18%, compared to VLXC's ROE of +0.68%. Regarding short-term risk, UHS is more volatile compared to VLXC. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, RHE has a market cap of 5.21M. Regarding current trading prices, UHS is priced at $181.80, while RHE trades at $2.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas RHE's P/E ratio is -1.79. In terms of profitability, UHS's ROE is +0.18%, compared to RHE's ROE of +2.66%. Regarding short-term risk, UHS is less volatile compared to RHE. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, TOIIW has a market cap of 4.98M. Regarding current trading prices, UHS is priced at $181.80, while TOIIW trades at $0.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas TOIIW's P/E ratio is N/A. In terms of profitability, UHS's ROE is +0.18%, compared to TOIIW's ROE of -2.73%. Regarding short-term risk, UHS is less volatile compared to TOIIW. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, RHEP has a market cap of 4.94M. Regarding current trading prices, UHS is priced at $181.80, while RHEP trades at $2.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas RHEP's P/E ratio is -1.34. In terms of profitability, UHS's ROE is +0.18%, compared to RHEP's ROE of N/A. Regarding short-term risk, UHS is less volatile compared to RHEP. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, BICX has a market cap of 4.62M. Regarding current trading prices, UHS is priced at $181.80, while BICX trades at $0.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas BICX's P/E ratio is -0.59. In terms of profitability, UHS's ROE is +0.18%, compared to BICX's ROE of +0.45%. Regarding short-term risk, UHS is more volatile compared to BICX. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, ATIP has a market cap of 3.71M. Regarding current trading prices, UHS is priced at $181.80, while ATIP trades at $0.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas ATIP's P/E ratio is -0.04. In terms of profitability, UHS's ROE is +0.18%, compared to ATIP's ROE of +1.77%. Regarding short-term risk, UHS is more volatile compared to ATIP. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, KDLYW has a market cap of 2.78M. Regarding current trading prices, UHS is priced at $181.80, while KDLYW trades at $0.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas KDLYW's P/E ratio is N/A. In terms of profitability, UHS's ROE is +0.18%, compared to KDLYW's ROE of -1.44%. Regarding short-term risk, UHS is less volatile compared to KDLYW. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, EPWCF has a market cap of 2.54M. Regarding current trading prices, UHS is priced at $181.80, while EPWCF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas EPWCF's P/E ratio is N/A. In terms of profitability, UHS's ROE is +0.18%, compared to EPWCF's ROE of +0.00%. Regarding short-term risk, UHS is less volatile compared to EPWCF. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, GRST has a market cap of 2.32M. Regarding current trading prices, UHS is priced at $181.80, while GRST trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas GRST's P/E ratio is N/A. In terms of profitability, UHS's ROE is +0.18%, compared to GRST's ROE of +0.30%. Regarding short-term risk, UHS is more volatile compared to GRST. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, JRSS has a market cap of 1.95M. Regarding current trading prices, UHS is priced at $181.80, while JRSS trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas JRSS's P/E ratio is -0.38. In terms of profitability, UHS's ROE is +0.18%, compared to JRSS's ROE of +2.63%. Regarding short-term risk, UHS is less volatile compared to JRSS. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, TOKIF has a market cap of 1.78M. Regarding current trading prices, UHS is priced at $181.80, while TOKIF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas TOKIF's P/E ratio is -0.01. In terms of profitability, UHS's ROE is +0.18%, compared to TOKIF's ROE of -0.83%. Regarding short-term risk, UHS is less volatile compared to TOKIF. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, IMACW has a market cap of 1.74M. Regarding current trading prices, UHS is priced at $181.80, while IMACW trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas IMACW's P/E ratio is N/A. In terms of profitability, UHS's ROE is +0.18%, compared to IMACW's ROE of +2.46%. Regarding short-term risk, UHS is less volatile compared to IMACW. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, SMAS has a market cap of 1.46M. Regarding current trading prices, UHS is priced at $181.80, while SMAS trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas SMAS's P/E ratio is N/A. In terms of profitability, UHS's ROE is +0.18%, compared to SMAS's ROE of N/A. Regarding short-term risk, UHS is less volatile compared to SMAS. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, MDGP has a market cap of 1.45M. Regarding current trading prices, UHS is priced at $181.80, while MDGP trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas MDGP's P/E ratio is N/A. In terms of profitability, UHS's ROE is +0.18%, compared to MDGP's ROE of N/A. Regarding short-term risk, UHS is more volatile compared to MDGP. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, NOVC has a market cap of 1.16M. Regarding current trading prices, UHS is priced at $181.80, while NOVC trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas NOVC's P/E ratio is -0.20. In terms of profitability, UHS's ROE is +0.18%, compared to NOVC's ROE of +0.12%. Regarding short-term risk, UHS is more volatile compared to NOVC. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, PHMB has a market cap of 1.08M. Regarding current trading prices, UHS is priced at $181.80, while PHMB trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas PHMB's P/E ratio is N/A. In terms of profitability, UHS's ROE is +0.18%, compared to PHMB's ROE of N/A. Regarding short-term risk, UHS is less volatile compared to PHMB. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, CCM has a market cap of 1.07M. Regarding current trading prices, UHS is priced at $181.80, while CCM trades at $7.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas CCM's P/E ratio is -0.76. In terms of profitability, UHS's ROE is +0.18%, compared to CCM's ROE of +0.13%. Regarding short-term risk, UHS is less volatile compared to CCM. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, SYRA has a market cap of 952999.00. Regarding current trading prices, UHS is priced at $181.80, while SYRA trades at $0.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas SYRA's P/E ratio is -0.16. In terms of profitability, UHS's ROE is +0.18%, compared to SYRA's ROE of -1.28%. Regarding short-term risk, UHS is less volatile compared to SYRA. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, GNOW has a market cap of 859731.00. Regarding current trading prices, UHS is priced at $181.80, while GNOW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas GNOW's P/E ratio is -0.01. In terms of profitability, UHS's ROE is +0.18%, compared to GNOW's ROE of +0.00%. Regarding short-term risk, UHS is more volatile compared to GNOW. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, RHE-PA has a market cap of 674535.00. Regarding current trading prices, UHS is priced at $181.80, while RHE-PA trades at $0.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas RHE-PA's P/E ratio is -0.09. In terms of profitability, UHS's ROE is +0.18%, compared to RHE-PA's ROE of +2.66%. Regarding short-term risk, UHS is less volatile compared to RHE-PA. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, DPAT has a market cap of 397353.00. Regarding current trading prices, UHS is priced at $181.80, while DPAT trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas DPAT's P/E ratio is -1.65. In terms of profitability, UHS's ROE is +0.18%, compared to DPAT's ROE of +0.45%. Regarding short-term risk, UHS is more volatile compared to DPAT. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, ARPC has a market cap of 336555.00. Regarding current trading prices, UHS is priced at $181.80, while ARPC trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas ARPC's P/E ratio is N/A. In terms of profitability, UHS's ROE is +0.18%, compared to ARPC's ROE of -0.56%. Regarding short-term risk, UHS is less volatile compared to ARPC. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, NXGT has a market cap of 332870.00. Regarding current trading prices, UHS is priced at $181.80, while NXGT trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas NXGT's P/E ratio is N/A. In terms of profitability, UHS's ROE is +0.18%, compared to NXGT's ROE of +0.09%. Regarding short-term risk, UHS is more volatile compared to NXGT. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, KJFI has a market cap of 278854.00. Regarding current trading prices, UHS is priced at $181.80, while KJFI trades at $0.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas KJFI's P/E ratio is -0.06. In terms of profitability, UHS's ROE is +0.18%, compared to KJFI's ROE of +0.00%. Regarding short-term risk, UHS is more volatile compared to KJFI. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, FCHS has a market cap of 263666.00. Regarding current trading prices, UHS is priced at $181.80, while FCHS trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas FCHS's P/E ratio is -0.07. In terms of profitability, UHS's ROE is +0.18%, compared to FCHS's ROE of +0.12%. Regarding short-term risk, UHS is less volatile compared to FCHS. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, JNHMF has a market cap of 165397.00. Regarding current trading prices, UHS is priced at $181.80, while JNHMF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas JNHMF's P/E ratio is -0.07. In terms of profitability, UHS's ROE is +0.18%, compared to JNHMF's ROE of +0.81%. Regarding short-term risk, UHS is less volatile compared to JNHMF. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, HSMD has a market cap of 153388.00. Regarding current trading prices, UHS is priced at $181.80, while HSMD trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas HSMD's P/E ratio is -0.05. In terms of profitability, UHS's ROE is +0.18%, compared to HSMD's ROE of -0.04%. Regarding short-term risk, UHS is more volatile compared to HSMD. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, SETO has a market cap of 150935.00. Regarding current trading prices, UHS is priced at $181.80, while SETO trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas SETO's P/E ratio is -1.21. In terms of profitability, UHS's ROE is +0.18%, compared to SETO's ROE of +0.00%. Regarding short-term risk, UHS is more volatile compared to SETO. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, BNYN has a market cap of 150549.00. Regarding current trading prices, UHS is priced at $181.80, while BNYN trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas BNYN's P/E ratio is N/A. In terms of profitability, UHS's ROE is +0.18%, compared to BNYN's ROE of -14.10%. Regarding short-term risk, UHS is less volatile compared to BNYN. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, BACK has a market cap of 119605.00. Regarding current trading prices, UHS is priced at $181.80, while BACK trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas BACK's P/E ratio is -0.01. In terms of profitability, UHS's ROE is +0.18%, compared to BACK's ROE of +2.46%. Regarding short-term risk, UHS is more volatile compared to BACK. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, TPIA has a market cap of 113827.00. Regarding current trading prices, UHS is priced at $181.80, while TPIA trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas TPIA's P/E ratio is -0.15. In terms of profitability, UHS's ROE is +0.18%, compared to TPIA's ROE of +0.61%. Regarding short-term risk, UHS is less volatile compared to TPIA. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, COLRF has a market cap of 108333.00. Regarding current trading prices, UHS is priced at $181.80, while COLRF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas COLRF's P/E ratio is -0.01. In terms of profitability, UHS's ROE is +0.18%, compared to COLRF's ROE of +0.02%. Regarding short-term risk, UHS is more volatile compared to COLRF. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, AMBD has a market cap of 85625.00. Regarding current trading prices, UHS is priced at $181.80, while AMBD trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas AMBD's P/E ratio is N/A. In terms of profitability, UHS's ROE is +0.18%, compared to AMBD's ROE of N/A. Regarding short-term risk, UHS is less volatile compared to AMBD. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, NMHLY has a market cap of 41741.00. Regarding current trading prices, UHS is priced at $181.80, while NMHLY trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas NMHLY's P/E ratio is 0.02. In terms of profitability, UHS's ROE is +0.18%, compared to NMHLY's ROE of N/A. Regarding short-term risk, UHS is more volatile compared to NMHLY. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, GENN has a market cap of 32696.00. Regarding current trading prices, UHS is priced at $181.80, while GENN trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas GENN's P/E ratio is -0.02. In terms of profitability, UHS's ROE is +0.18%, compared to GENN's ROE of +0.00%. Regarding short-term risk, UHS is more volatile compared to GENN. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, DRWN has a market cap of 23978.00. Regarding current trading prices, UHS is priced at $181.80, while DRWN trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas DRWN's P/E ratio is N/A. In terms of profitability, UHS's ROE is +0.18%, compared to DRWN's ROE of -0.01%. Regarding short-term risk, UHS is less volatile compared to DRWN. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, NVOS has a market cap of 23676.00. Regarding current trading prices, UHS is priced at $181.80, while NVOS trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas NVOS's P/E ratio is N/A. In terms of profitability, UHS's ROE is +0.18%, compared to NVOS's ROE of -1.20%. Regarding short-term risk, UHS is less volatile compared to NVOS. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, CLRD has a market cap of 21647.00. Regarding current trading prices, UHS is priced at $181.80, while CLRD trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas CLRD's P/E ratio is N/A. In terms of profitability, UHS's ROE is +0.18%, compared to CLRD's ROE of +0.38%. Regarding short-term risk, UHS is less volatile compared to CLRD. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, SCAL has a market cap of 17424.00. Regarding current trading prices, UHS is priced at $181.80, while SCAL trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas SCAL's P/E ratio is 0.04. In terms of profitability, UHS's ROE is +0.18%, compared to SCAL's ROE of +0.07%. Regarding short-term risk, UHS is more volatile compared to SCAL. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, CHCR has a market cap of 11991.00. Regarding current trading prices, UHS is priced at $181.80, while CHCR trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas CHCR's P/E ratio is -0.00. In terms of profitability, UHS's ROE is +0.18%, compared to CHCR's ROE of N/A. Regarding short-term risk, UHS is more volatile compared to CHCR. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, ACGI has a market cap of 10477.00. Regarding current trading prices, UHS is priced at $181.80, while ACGI trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas ACGI's P/E ratio is N/A. In terms of profitability, UHS's ROE is +0.18%, compared to ACGI's ROE of +1.11%. Regarding short-term risk, UHS is less volatile compared to ACGI. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, CEVE has a market cap of 7709.00. Regarding current trading prices, UHS is priced at $181.80, while CEVE trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas CEVE's P/E ratio is N/A. In terms of profitability, UHS's ROE is +0.18%, compared to CEVE's ROE of N/A. Regarding short-term risk, UHS is more volatile compared to CEVE. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, NAFS has a market cap of 7007.00. Regarding current trading prices, UHS is priced at $181.80, while NAFS trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas NAFS's P/E ratio is N/A. In terms of profitability, UHS's ROE is +0.18%, compared to NAFS's ROE of +1.02%. Regarding short-term risk, UHS is more volatile compared to NAFS. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, PRMD has a market cap of 5610.00. Regarding current trading prices, UHS is priced at $181.80, while PRMD trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas PRMD's P/E ratio is N/A. In terms of profitability, UHS's ROE is +0.18%, compared to PRMD's ROE of +0.73%. Regarding short-term risk, UHS is less volatile compared to PRMD. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, MSGP has a market cap of 5191.00. Regarding current trading prices, UHS is priced at $181.80, while MSGP trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas MSGP's P/E ratio is N/A. In terms of profitability, UHS's ROE is +0.18%, compared to MSGP's ROE of +0.27%. Regarding short-term risk, UHS is more volatile compared to MSGP. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, MSITF has a market cap of 4800.00. Regarding current trading prices, UHS is priced at $181.80, while MSITF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas MSITF's P/E ratio is -0.00. In terms of profitability, UHS's ROE is +0.18%, compared to MSITF's ROE of N/A. Regarding short-term risk, UHS is more volatile compared to MSITF. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, ERUC has a market cap of 3915.00. Regarding current trading prices, UHS is priced at $181.80, while ERUC trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas ERUC's P/E ratio is N/A. In terms of profitability, UHS's ROE is +0.18%, compared to ERUC's ROE of N/A. Regarding short-term risk, UHS is less volatile compared to ERUC. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, SLHPF has a market cap of 3901.00. Regarding current trading prices, UHS is priced at $181.80, while SLHPF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas SLHPF's P/E ratio is N/A. In terms of profitability, UHS's ROE is +0.18%, compared to SLHPF's ROE of +0.00%. Regarding short-term risk, UHS is less volatile compared to SLHPF. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, WEQL has a market cap of 3534.00. Regarding current trading prices, UHS is priced at $181.80, while WEQL trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas WEQL's P/E ratio is N/A. In terms of profitability, UHS's ROE is +0.18%, compared to WEQL's ROE of N/A. Regarding short-term risk, UHS is more volatile compared to WEQL. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, BBAL has a market cap of 3354.00. Regarding current trading prices, UHS is priced at $181.80, while BBAL trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas BBAL's P/E ratio is N/A. In terms of profitability, UHS's ROE is +0.18%, compared to BBAL's ROE of N/A. Regarding short-term risk, UHS is more volatile compared to BBAL. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, PAOG has a market cap of 2478.00. Regarding current trading prices, UHS is priced at $181.80, while PAOG trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas PAOG's P/E ratio is N/A. In terms of profitability, UHS's ROE is +0.18%, compared to PAOG's ROE of +0.08%. Regarding short-term risk, UHS is less volatile compared to PAOG. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, NMMCF has a market cap of 2087.00. Regarding current trading prices, UHS is priced at $181.80, while NMMCF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas NMMCF's P/E ratio is 0.00. In terms of profitability, UHS's ROE is +0.18%, compared to NMMCF's ROE of +0.00%. Regarding short-term risk, UHS is less volatile compared to NMMCF. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, PPRG has a market cap of 1580.00. Regarding current trading prices, UHS is priced at $181.80, while PPRG trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas PPRG's P/E ratio is N/A. In terms of profitability, UHS's ROE is +0.18%, compared to PPRG's ROE of N/A. Regarding short-term risk, UHS is more volatile compared to PPRG. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, NIVFW has a market cap of 1571.00. Regarding current trading prices, UHS is priced at $181.80, while NIVFW trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas NIVFW's P/E ratio is N/A. In terms of profitability, UHS's ROE is +0.18%, compared to NIVFW's ROE of -0.39%. Regarding short-term risk, UHS is less volatile compared to NIVFW. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, OHAQ has a market cap of 1375.00. Regarding current trading prices, UHS is priced at $181.80, while OHAQ trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas OHAQ's P/E ratio is 0.01. In terms of profitability, UHS's ROE is +0.18%, compared to OHAQ's ROE of N/A. Regarding short-term risk, UHS is more volatile compared to OHAQ. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, BNKL has a market cap of 1248.00. Regarding current trading prices, UHS is priced at $181.80, while BNKL trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas BNKL's P/E ratio is N/A. In terms of profitability, UHS's ROE is +0.18%, compared to BNKL's ROE of -7.69%. Regarding short-term risk, UHS is more volatile compared to BNKL. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, MAHN has a market cap of 1211.00. Regarding current trading prices, UHS is priced at $181.80, while MAHN trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas MAHN's P/E ratio is 0.05. In terms of profitability, UHS's ROE is +0.18%, compared to MAHN's ROE of N/A. Regarding short-term risk, UHS is less volatile compared to MAHN. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, SLHGF has a market cap of 398.00. Regarding current trading prices, UHS is priced at $181.80, while SLHGF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas SLHGF's P/E ratio is -0.00. In terms of profitability, UHS's ROE is +0.18%, compared to SLHGF's ROE of +0.00%. Regarding short-term risk, UHS is more volatile compared to SLHGF. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, LHRP has a market cap of 340.00. Regarding current trading prices, UHS is priced at $181.80, while LHRP trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas LHRP's P/E ratio is 0.00. In terms of profitability, UHS's ROE is +0.18%, compared to LHRP's ROE of N/A. Regarding short-term risk, UHS is more volatile compared to LHRP. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, IONM has a market cap of 313.00. Regarding current trading prices, UHS is priced at $181.80, while IONM trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas IONM's P/E ratio is N/A. In terms of profitability, UHS's ROE is +0.18%, compared to IONM's ROE of +0.75%. Regarding short-term risk, UHS is less volatile compared to IONM. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, NMSCA has a market cap of 275.00. Regarding current trading prices, UHS is priced at $181.80, while NMSCA trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas NMSCA's P/E ratio is N/A. In terms of profitability, UHS's ROE is +0.18%, compared to NMSCA's ROE of N/A. Regarding short-term risk, UHS is more volatile compared to NMSCA. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, INDR has a market cap of 132.00. Regarding current trading prices, UHS is priced at $181.80, while INDR trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas INDR's P/E ratio is -0.00. In terms of profitability, UHS's ROE is +0.18%, compared to INDR's ROE of N/A. Regarding short-term risk, UHS is more volatile compared to INDR. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, NRTSF has a market cap of 78.00. Regarding current trading prices, UHS is priced at $181.80, while NRTSF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas NRTSF's P/E ratio is 0.00. In terms of profitability, UHS's ROE is +0.18%, compared to NRTSF's ROE of +0.00%. Regarding short-term risk, UHS is more volatile compared to NRTSF. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, SDNI has a market cap of 18.00. Regarding current trading prices, UHS is priced at $181.80, while SDNI trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas SDNI's P/E ratio is N/A. In terms of profitability, UHS's ROE is +0.18%, compared to SDNI's ROE of N/A. Regarding short-term risk, UHS is more volatile compared to SDNI. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, ROIX has a market cap of 12.00. Regarding current trading prices, UHS is priced at $181.80, while ROIX trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas ROIX's P/E ratio is -0.00. In terms of profitability, UHS's ROE is +0.18%, compared to ROIX's ROE of N/A. Regarding short-term risk, UHS is more volatile compared to ROIX. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, HNGR comparison data is unavailable. Regarding current trading prices, UHS is priced at $181.80, while HNGR trades at $18.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas HNGR's P/E ratio is 19.71. In terms of profitability, UHS's ROE is +0.18%, compared to HNGR's ROE of +0.52%. Regarding short-term risk, UHS is more volatile compared to HNGR. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, SLHG comparison data is unavailable. Regarding current trading prices, UHS is priced at $181.80, while SLHG trades at $0.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas SLHG's P/E ratio is -1.48. In terms of profitability, UHS's ROE is +0.18%, compared to SLHG's ROE of N/A. Regarding short-term risk, UHS is less volatile compared to SLHG. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, BDYS comparison data is unavailable. Regarding current trading prices, UHS is priced at $181.80, while BDYS trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas BDYS's P/E ratio is N/A. In terms of profitability, UHS's ROE is +0.18%, compared to BDYS's ROE of N/A. Regarding short-term risk, UHS is less volatile compared to BDYS. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, NFH comparison data is unavailable. Regarding current trading prices, UHS is priced at $181.80, while NFH trades at $11.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas NFH's P/E ratio is -19.75. In terms of profitability, UHS's ROE is +0.18%, compared to NFH's ROE of -0.06%. Regarding short-term risk, UHS is more volatile compared to NFH. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, TLMDW comparison data is unavailable. Regarding current trading prices, UHS is priced at $181.80, while TLMDW trades at $0.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas TLMDW's P/E ratio is N/A. In terms of profitability, UHS's ROE is +0.18%, compared to TLMDW's ROE of -0.46%. Regarding short-term risk, UHS is less volatile compared to TLMDW. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, BKDTU comparison data is unavailable. Regarding current trading prices, UHS is priced at $181.80, while BKDTU trades at $50.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas BKDTU's P/E ratio is N/A. In terms of profitability, UHS's ROE is +0.18%, compared to BKDTU's ROE of N/A. Regarding short-term risk, UHS is more volatile compared to BKDTU. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, DVCR comparison data is unavailable. Regarding current trading prices, UHS is priced at $181.80, while DVCR trades at $10.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas DVCR's P/E ratio is 28.34. In terms of profitability, UHS's ROE is +0.18%, compared to DVCR's ROE of -0.15%. Regarding short-term risk, UHS is more volatile compared to DVCR. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, DCGOW comparison data is unavailable. Regarding current trading prices, UHS is priced at $181.80, while DCGOW trades at $1.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas DCGOW's P/E ratio is N/A. In terms of profitability, UHS's ROE is +0.18%, compared to DCGOW's ROE of +0.00%. Regarding short-term risk, UHS is less volatile compared to DCGOW. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, TVTY comparison data is unavailable. Regarding current trading prices, UHS is priced at $181.80, while TVTY trades at $32.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas TVTY's P/E ratio is 19.06. In terms of profitability, UHS's ROE is +0.18%, compared to TVTY's ROE of +1.75%. Regarding short-term risk, UHS is more volatile compared to TVTY. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, TLMD comparison data is unavailable. Regarding current trading prices, UHS is priced at $181.80, while TLMD trades at $3.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas TLMD's P/E ratio is -1.60. In terms of profitability, UHS's ROE is +0.18%, compared to TLMD's ROE of -0.46%. Regarding short-term risk, UHS is more volatile compared to TLMD. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.

UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UHS stands at 11.85B. In comparison, SLHGP comparison data is unavailable. Regarding current trading prices, UHS is priced at $181.80, while SLHGP trades at $12.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UHS currently has a P/E ratio of 10.21, whereas SLHGP's P/E ratio is -30.38. In terms of profitability, UHS's ROE is +0.18%, compared to SLHGP's ROE of -0.71%. Regarding short-term risk, UHS is more volatile compared to SLHGP. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.